focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCoca-cola Euro. Regulatory News (CCEP)

Share Price Information for Coca-cola Euro. (CCEP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 69.00
Bid: 68.60
Ask: 69.00
Change: 0.00 (0.00%)
Spread: 0.40 (0.583%)
Open: 69.00
High: 69.60
Low: 69.00
Prev. Close: 69.00
CCEP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Letter to Shareholders

15 May 2019 09:50

RNS Number : 1006Z
Coca-Cola European Partners plc
15 May 2019
 

Coca-Cola European Partners plc (CCEP)

 

15 May 2019

 

Dear Shareholder of Coca-Cola European Partners plc:

We are writing to ask for your support by voting "FOR" all resolutions, as recommended by the Board of Directors, at our upcoming 2019 Annual General Meeting on 29 May 2019.

Certain proxy advisory services reports contain conflicting advice on Resolution 17 (Waiver of mandatory offer provisions set out in Rule 9 of the Takeover Code), Resolution 22 (Amendment of the Articles of Association) and Resolutions 8 and 12 (Re-election of Irial Finan and Mario Rotllant Solá, respectively) and we want to provide additional context regarding these resolutions beyond that in our Notice of Meeting.

Resolution 17 (Waiver of mandatory offer provisions set out in Rule 9 of the Takeover Code)

The report issued by Glass, Lewis & Co. (Glass Lewis) recommends a vote "FOR" Resolution 17. The report generated by Institutional Shareholder Services (ISS) recommends a vote "AGAINST" Resolution 17. Both Glass Lewis and ISS have recommended voting "FOR" Resolutions 19 and 20 (Authorities to purchase own shares).

A share repurchase will not occur unless BOTH Resolution 17 AND Resolutions 19 and 20 are approved. Therefore, a vote "AGAINST" Resolution 17 will have the same practical effect as a vote "AGAINST" Resolutions 19 and 20.

The report issued by Glass Lewis states:

"We believe the terms of this proposal are reasonable.

We do not believe that this proposal is connected with any sort of takeover attempt by this party, and thus, we do not believe this proposal should warrant shareholder concern at this time."

On the other hand, ISS recommended "AGAINST" Resolution 17 based on the application of its standard policy. We believe that ISS's undefined "concerns over creeping control" fail to take into account certain important facts.

Rule 9 of the Takeover Code applies when any entity holds 30% or more of the voting rights of a company. When a company purchases its own voting shares, any resulting increase in the percentage of shares carrying voting rights will be an acquisition for the purpose of Rule 9. CCEP currently has one shareholder, Olive Partners, S.A. (Olive), which owns approximately 35% of our outstanding shares and so any share repurchase would trigger Rule 9 of the Takeover Code.

Olive has confirmed that it has no intention of changing its approach with respect to CCEP as a result of any increase in its shareholding due to any share repurchase. It has no intention to seek any change in the composition of the Board or to the general nature or any other aspect of the Company's business. Given Olive's stated position, we believe that any concerns over "creeping control" are therefore unfounded.

As noted above, a share repurchase will not occur unless BOTH Resolution 17 and Resolutions 19/20 are approved.

The CCEP Board and management firmly believe these resolutions are in the best interests of shareholders as they provide the ability to repurchase shares, enabling our Company to continue to deliver long-term shareholder value. Accordingly, the Board and management of CCEP recommend voting "FOR" Resolutions 17, 19 and 20, consistent with the recommendation of Glass Lewis.

Resolution 22 (Adopt new articles of association)

Glass Lewis recommended voting "FOR" Resolution 22, stating:

"Glass Lewis generally supports changes made to the articles of association that do not act contrary to shareholders' interest. In this case, we believe that the proposed changes will not have a significant effect on the Company's shareholders."

The report generated by ISS recommends a vote "AGAINST" Resolution 22 on the basis of its standard policy that a director who appoints, or who is appointed as, an alternate director "may not be considered to be independent".

CCEP's Articles of Association require, amongst other things, independent Non-executive Directors (INEDs) to constitute a majority of the directors present for a Board meeting to be quorate. This is seen as an important protection for shareholders. The purpose of the proposed changes is to ensure that a meeting will not be inquorate by virtue of an INED being unable to attend a Board meeting given the number of INEDs relative to other directors. Under the proposed change, an INED may only appoint another INED as their alternate (see new Article 87.(A)(ii)). For this reason, we believe that ISS's concern regarding the non-independence of an alternate is unfounded.

Resolution 22 also contains proposals to allow the number of directors on the Board to exceed the current limit of 17. This proposal is made to allow the Company the flexibility to appoint additional directors. The requirement under the Articles that the Board contain a majority of independent directors at all times is not affected. It is the Board's intention (i) to appoint more than 17 directors only in limited circumstances, (ii) to make appointments in line with our Criteria for selection of INEDs (available on our website at ir.ccep.com) and (iii) to return the number of directors to no more than 17 at the annual general meeting following the appointment of any additional director. A vote against Resolution 22 for the reasons set out by ISS will also be a vote against this proposal.

The CCEP Board and management firmly believes this resolution is in the best interests of shareholders and recommends voting "FOR" Resolution 22, consistent with the recommendation of Glass Lewis.

Resolutions 8 and 12 (re-election of Irial Finan and Mario Rotllant Solá, respectively)

The report issued by Glass Lewis recommends votes "FOR" Resolution 8 (the re-election of Irial Finan) and Resolution 12 (the re-election of Mario Rotllant Solá. The report states:

"The remuneration committee includes two shareholder representatives, one nominated by each of the largest shareholders. The UK Code stipulates that the remuneration committee comprise independent NEDs.

However, in this case, as noted above, Olive Partners SA and European Refreshments own 35% and 18% of shares, respectively and are entitled to nominate a director to the committee. We generally believe that persons or entities with a significant portion of the Company's voting power should be entitled to representation in proportion to its ownership interest on the Company's board and committees, with the exception of the Company's audit committee. As such, we will refrain from recommending that shareholders vote against affiliated directors based on the composition of the remuneration committee.

Having reviewed the nominees, and in the context of the Company's ownership and considering it is not obliged to apply to the Code, we do not believe there are substantial issues for shareholder concern."

The report generated by ISS notes that its policy requires remuneration committees to be comprised solely of independent directors. It therefore recommends a vote "AGAINST" the re-election of the two non-independent members of CCEP's Remuneration Committee. We note that in previous years ISS has not recommended a vote against Mr. Finan or Mr Rotllant Solá notwithstanding that they have been members of the Remuneration Committee since 2016.

The CCEP Board and Remuneration Committee Chairman, Christine Cross, are of the opinion that the re-election of Mr. Finan and Mr. Rotllant Solá is appropriate because:

• the presence of Mr. Finan and Mr. Rotllant Solá on the Remuneration Committee does not render it insufficiently independent because the Committee has a majority of INEDs;

• the terms of reference of the Remuneration Committee stipulate that it must be composed of a majority of INEDs, including for quorum requirements; and

• Mr Finan and Mr. Rotllant Solá are not executive directors, but appointed representatives of the Company's largest shareholders - it is natural that these shareholders would want a say on the remuneration of senior executives.

The CCEP Board and management firmly believes this resolution is in the best interests of shareholders and recommends voting "FOR" Resolutions 8 and 12, consistent with the recommendation of Glass Lewis.

We would be glad to discuss the CCEP recommendations in relation to Resolutions 17, 22, 8 and 12 further with you, should you wish. If you have any questions, or need assistance in submitting your proxy to vote your shares, please contact our proxy solicitor, MacKenzie Partners, Inc., at +1 (800) 322-2885 or proxy@mackenziepartners.com.

Thank you for your support.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCCKPDBFBKKQPD
Date   Source Headline
10th May 20247:00 amRNSLetter to Shareholders
3rd May 20247:00 amRNSResignation of Chief Financial Officer
1st May 20243:00 pmRNSTotal Voting Rights
25th Apr 20247:00 amRNSQ1 Trading Update & Interim Dividend Declaration
24th Apr 20241:30 pmRNSDirector/PDMR Shareholding
17th Apr 20241:45 pmRNSDirector/PDMR Shareholding
10th Apr 20249:15 amRNSNotice of AGM
2nd Apr 20242:30 pmRNSTotal Voting Rights
21st Mar 20242:00 pmRNSDirector/PDMR Shareholding
20th Mar 20243:00 pmRNSDirector/PDMR Shareholding
18th Mar 20244:30 pmRNSBlock listing Interim Review
15th Mar 202411:59 amRNSAnnual Financial Report
1st Mar 20242:00 pmRNSTotal Voting Rights
23rd Feb 20247:00 amRNSCompletion of joint acquisition of CCBPI
23rd Feb 20247:00 amRNSPreliminary Unaudited Results Q4 & FY 2023
21st Feb 20245:00 pmRNSDirector/PDMR Shareholding
1st Feb 20242:30 pmRNSTotal Voting Rights
30th Jan 202411:30 amRNSPCC approval received to jointly acquire CCBPI
26th Jan 20244:15 pmRNSDirector/PDMR Shareholding - amendment
25th Jan 202410:30 amRNSDirector/PDMR Shareholding
22nd Jan 20243:15 pmRNSDirector/PDMR Shareholding
17th Jan 202411:30 amRNSDirector/PDMR Shareholding
2nd Jan 20241:30 pmRNSTotal Voting Rights
20th Dec 202311:15 amRNSDirector/PDMR Shareholding
18th Dec 202312:15 pmRNSDirector/PDMR Shareholding
15th Dec 20233:40 pmRNSDirector/PDMR Shareholding
14th Dec 202311:00 amRNSDirectorate Change
1st Dec 20231:45 pmRNSTotal Voting Rights
28th Nov 20234:00 pmRNSDirector/PDMR Shareholding
24th Nov 20232:30 pmRNSUpdate statement on 2023 AGM voting results
21st Nov 20234:30 pmRNSDirector/PDMR Shareholding
20th Nov 20237:00 amRNSUpdate re acquisition of CCBPI
1st Nov 20231:45 pmRNSTotal Voting Rights
1st Nov 20237:00 amRNSQ3 Trading Update & Interim Dividend Declaration
25th Oct 20231:30 pmRNSDirector/PDMR Shareholding
20th Oct 202312:00 pmRNSDirector/PDMR Shareholding
13th Oct 20232:30 pmRNSDirector/PDMR Shareholding
20th Sep 20234:45 pmRNSDirector/PDMR Shareholding
18th Sep 20234:50 pmRNSBlock listing Interim Review
1st Sep 20231:30 pmRNSTotal Voting Rights
22nd Aug 20233:00 pmRNSDirector/PDMR Shareholding
2nd Aug 20237:01 amRNSResults for the six months ended 30 June 2023
2nd Aug 20237:00 amRNSProposed joint acquisition of CCBPI
1st Aug 20231:05 pmRNSTotal Voting Rights
25th Jul 20234:00 pmRNSDirector/PDMR Shareholding
21st Jul 20232:30 pmRNSDirector/PDMR Shareholding
13th Jul 20233:30 pmRNSDirector/PDMR Shareholding
30th Jun 20234:30 pmRNSDirector/PDMR Shareholding
23rd Jun 20233:00 pmRNSDirector/PDMR Shareholding
8th Jun 202310:50 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.